Compare Danaher Corporation (DHR) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs OneSpan Inc — how do they compare? Danaher Corporation trades at $206.14 (market cap $145.83B), while OneSpan Inc trades at $16.25 (market cap $600.69M). The key difference: Danaher Corporation is far larger — about 242.8× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| DHR | OSPN | |
|---|---|---|
Market Cap | $145.83B | $600.69M |
Sector | Health | Technology |
52-Week High | $242.05 | $16.78 |
52-Week Low | $161.91 | $10.15 |
Enterprise Value | $168.04B | $569.77M |
Dividend Yield | 0.77% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
OneSpan (OSPN) trades at $16.21, down 0.98% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 9.21, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed revenue growth and raised full-year guidance, while the company continues paying $0.13 quarterly dividends.
Outlook remains positive with 67% analyst buy ratings and $17 consensus target offering 5% upside. Key risks include declining net cash flow and competitive pressures in the software sector. The stock presents value opportunity given attractive valuation multiples and strong profitability metrics, though investors should monitor execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
